Mipomersen
Kynamro (mipomersen) is an oligonucleotide pharmaceutical. Mipomersen was first approved as Kynamro on 2013-01-29. It is used to treat familial combined hyperlipidemia in the USA. Kynamro's patents are valid until 2027-01-29 (FDA).
| Trade Name | Kynamro |
|---|---|
| Common Name | Mipomersen |
| Indication | familial combined hyperlipidemia |
| Drug Class | Antisense oligonucleotides |
